BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 21173604)

  • 1. Neoadjuvant and adjuvant strategies in renal cell carcinoma: more questions than answers.
    Homicsko K; Berthold DR
    Anticancer Drugs; 2011 Jan; 22 Suppl 1():S4-8. PubMed ID: 21173604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccine therapy in patients with renal cell carcinoma.
    Van Poppel H; Joniau S; Van Gool SW
    Eur Urol; 2009 Jun; 55(6):1333-42. PubMed ID: 19201522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant autologous tumour cell-lysate vaccine versus no adjuvant treatment in patients with M0 renal cell carcinoma after radical nephrectomy: 3-year interim analysis of a German multicentre phase-III trial.
    Doehn Ch; Richter A; Lehmacher W; Jocham D
    Folia Biol (Praha); 2003; 49(2):69-73. PubMed ID: 12779015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant and neoadjuvant therapy for gastric cancer.
    Kelsen DP
    Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and treatment of renal cell carcinoma in children: a report from the Polish pediatric rare tumor study group.
    Stachowicz-Stencel T; Bien E; Balcerska A; Godzinski J; Synakiewicz A; Perek-Polnik M; Kurylak A; Pietras W; Kuzmicz M; Mizia-Malarz A; Rybczynska A; Nurzynska-Flak J
    Klin Padiatr; 2011 May; 223(3):138-41. PubMed ID: 21509711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of renal cell cancer.
    Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
    Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant and adjuvant treatment of renal cell carcinoma.
    Thillai K; Allan S; Powles T; Rudman S; Chowdhury S
    Expert Rev Anticancer Ther; 2012 Jun; 12(6):765-76. PubMed ID: 22716493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis.
    Repmann R; Goldschmidt AJ; Richter A
    Anticancer Res; 2003; 23(2A):969-74. PubMed ID: 12820332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome.
    Wood CG
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):697s-702s. PubMed ID: 17255296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can vaccination or tyrosine kinase inhibitor therapy play a role in the adjuvant treatment of renal cell carcinoma?
    Brookman-May S; May M; Gilfrich C; Wieland WF; Burger M
    Expert Rev Anticancer Ther; 2010 Jun; 10(6):813-23. PubMed ID: 20553207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
    Bex A; Jonasch E; Kirkali Z; Mejean A; Mulders P; Oudard S; Patard JJ; Powles T; van Poppel H; Wood CG
    Eur Urol; 2010 Dec; 58(6):819-28. PubMed ID: 20828919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant therapy for renal cell carcinoma.
    Jacobsohn KM; Wood CG
    Semin Oncol; 2006 Oct; 33(5):576-82. PubMed ID: 17045086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant and neoadjuvant therapy for renal cell carcinoma: a survey of the Society of Urologic Oncology.
    Tobert CM; Uzzo RG; Wood CG; Lane BR
    Urol Oncol; 2013 Oct; 31(7):1316-20. PubMed ID: 22264501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in immune-based therapies of renal cell carcinoma.
    Lam JS; Belldegrun AS; Figlin RA
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1081-96. PubMed ID: 15606335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is there an indication for neoadjuvant or adjuvant systemic therapy in renal cell cancer?].
    Doehn C; Merseburger AS; Jocham D; Kuczyk MA
    Urologe A; 2007 Oct; 46(10):1371-2, 1374, 1376-8. PubMed ID: 17805507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
    Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
    Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of cytoreductive nephrectomy in the era of molecular targeted therapy.
    Polcari AJ; Gorbonos A; Milner JE; Flanigan RC
    Int J Urol; 2009 Mar; 16(3):227-33. PubMed ID: 19207114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of surgery in advanced renal cell carcinoma: cytoreductive nephrectomy and metastasectomy.
    Karam JA; Wood CG
    Hematol Oncol Clin North Am; 2011 Aug; 25(4):753-64. PubMed ID: 21763966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.